Glenmark to market Tiotropium Bromide inhaler in Europe

Glenmark Pharmaceuticals Europe has entered into a strategic licensing agreement to market generic Tiotropium Bromide dry powder inhaler (DPI) in Western Europe.

Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim’s Spiriva Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD). This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/ Salmeterol dry powder inhaler.

Boehringer Ingelheim’s Spiriva Handihaler has recorded sales of US$ 724 million in the EU region for the 12-month period ended March 2018, according to IQVIA data.

On Wednesday, the share of Glenmark Pharmaceuticals opened at Rs 656.85 per share against its previous close of Rs. 643.40. It reached an intraday high of Rs. 656.85 per share and an intraday low of Rs. 645 per share on the BSE. Its 52-week high was Rs. 666 per share and its 52-week low was Rs. 483.60 per share on the BSE.

At 11:40 hours, the shares of the company was at Rs. 644 per share up by 0.16 per cent. Meanwhile, BSE Sensex was at 38,897.26 level down by 0.01 and Nifty50 was down by 0.02 at 11,736 level.